AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will webcast its Analyst and Investor meeting taking place on June 6, 2008 in New York City beginning at 8:00 am ET. At the meeting, the Company intends to discuss the ferumoxytol development program, the chronic kidney disease market generally, clinical perspectives on the treatment of iron deficiency anemia, the Company’s commercial strategy and manufacturing plans, potential ferumoxytol growth opportunities, and the Company’s business development plans and financial condition. The meeting will last approximately three and one-half hours.
A live audio webcast, including slides of the presentations, will be accessible through the Investors section of the Company’s website at www.amagpharma.com. Following the meeting, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until July 6, 2008.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.
Ferumoxytol, the Company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in chronic kidney disease patients. The Company has released data on all four planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic agent in chronic kidney disease patients. The Company submitted a New Drug Application for marketing approval of ferumoxytol with the U.S. Food and Drug Administration (FDA) in December 2007, which was accepted for filing by the FDA in February 2008.
Contacts:
Kristen Galfetti, 617-498-3362
kgalfetti@amagpharma.com
